The U.S. Mint has unveiled coins designs for America's 250th independence anniversary next year, featuring classical depictions of founding documents and the Revolutionary War. Donald Trump is notably ...

There are several rare coins out there that could be worth much more than their face value thanks to unique designs or printing errors – and here are five of the rarest Finding one of these five coins ...

New coins will bring a change to your pocket change in 2026. The United States Mint is set to roll out five new quarters and a dime to mark the nation's 250th anniversary. Officials unveiled the coins ...

The next signs of the nation’s political divide might be jingling in your pocket next year. The administration plans to issue a $1 coin with President Donald Trump’s likeness on it next year, despite ...

FIRST ON FOX: Secretary of the Treasury Scott Bessent scrapped Biden-era coin designs intended to celebrate the 250th anniversary of America’s founding after the Trump administration discovered they ...

DIBOLL — Council members learned that Diboll has recovered nearly $80,000 in delinquent taxes between July and November, as the city’s longtime collection firm reported Tuesday, while also adopting a ...

Advanced practice providers have been on strike since Dec. 2. Darcelle XV carries on drag queen's legacy by giving back through Christmas Eve dinner Volunteers and employees of Darcelle XV in Portland ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...